Trial document





This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00006537

Trial Description

start of 1:1-Block title

Title

Pyruvate Kinase Deficiency (PKD) Natural History Study

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

PKD NHS

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The purpose of this study is to describe the range and incidence of symptoms, treatments,
and complications related to pyruvate kinase deficiency (PKD). Eligible patients are those
of all ages with known PKD or with a hemolytic anemia and a family member with PKD. The
study will collect retrospective medical history, routine clinical care data, and quality of
life measures at baseline and annually for patients with PKD.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The purpose of the Pyruvate Kinase Deficiency (PKD) Natural History Study is to describe the
natural history of PKD and the range and incidence of symptoms, treatments, and
complications related to PKD. The study will collect retrospective medical history and
routine clinical care data at baseline and annually for patients with PKD. Patients without
a genetic diagnosis will have a blood sample drawn for genetic diagnostic confirmation for
research purposes. Understanding the clinical variation among participants with PKD, and
assessing treatments specific to PKD and their outcomes will accelerate improvement in the
care of patients with PKD. Understanding the natural history of PKD may be useful in the
design of future interventional studies. Detailed genotypic and phenotypic characterization
of the cohort will allow for continued in depth characterization of PKD. Finally, the PKD
Natural History Study will identify interested participants for future PKD studies.

Primary Objectives:

1. To estimate the transfusion burden in splenectomized and non-splenectomized
participants with PKD.

2. To establish a patient registry as a potential source for recruitment to future
research studies in PKD.

Secondary Objectives:

1. To determine if patient-reported outcomes, including quality of life and fatigue
scales, are associated with age, genotype, hemoglobin nadir, and/or transfusion burden,
overall and within the subgroups of splenectomized vs. non-splenectomized participants;

2. To describe changes over time in the range of hemoglobin values and markers of
hemolysis within individual participants and among participants with PKD;

3. To estimate the incidence of past splenectomy and annual splenectomy rate, as treatment
for PKD;

4. To estimate the prevalence and severity and describe the treatment of hepatic and
cardiac iron overload and its complications in PKD (liver, cardiac, growth defects,
hypogonadotropic hypogonadism, and other endocrine defects). To describe the changes
in these complications that may occur over time and by age group;

5. To estimate the prevalence of co-morbidities associated with chronic hemolysis in PKD,
to identify which co-morbidities are the most common, and to determine if the
prevalence and/or severity of co-morbidities change over time and by age at the time of
the first appearance of the co-morbidity;

6. To determine pregnancy outcomes among participants with PKD;

7. To describe genotypic and phenotypic variation among participants and explore
genotype-phenotype correlation in PKD.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00006537
  •   2014/07/23
  •   2014/01/28
  •   yes
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT02053480  (ClinicalTrials.gov)
  •   P00010515  (Children's Hospital Boston)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Pyruvate Kinase Deficiency
  •   Congenital Non-Spherocytic Hemolytic Anemia
  •   D55.2 -  Anaemia due to disorders of glycolytic enzymes
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  • [---]*
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Observational study
  •   [---]*
  •   [---]*
  •   [---]*
  •   [---]*
  •   [---]*
  •   [---]*
  •   N/A
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- transfusion burden in splenectomized and non-splenectomized participants; time frame: 12 weeks

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- patient-reported outcomes; time frame: enrollment, annually, up to 2 years; EuroQoL-5D-5L, Functional Assessment of Cancer Therapy-Anemia (FACT-An), Pediatric Quality of Life Inventory 4.0 (pedsQL 4.0), Pediatric Functional Assessment of Chronic Illness-Fatigue (pedsFACIT-F), Patient Reported Outcomes Measurement Information System Fatigue (PROMIS Fatigue)
- changes over time in hemoglobin and markers of hemolysis; time frame: enrollment, annually, up to 2 years
- prevalence and severity of iron overload; time frame: enrollment, annually, up to 2 years

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   United States
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • [---]*
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2013/12/31
  •   100
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   no minimum age
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- Patients of all ages with biochemically or genetically diagnosed PKD.

- Patients with a hemolytic anemia AND a family member with genetically diagnosed PKD

- The participant or the guardian of the participant is willing and able to give
written informed consent and/or assent.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- The participant or the guardian of the participant is unwilling or unable to give
written informed consent and/or assent.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Children's Hospital Boston
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address other
    • Agios Pharmaceuticals, Inc.
    end of 1:1-Block address other
    start of 1:1-Block address contact other
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact other
  • start of 1:1-Block address scientific-contact
    • Rachael F Grace, MD, MMSc 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Rachael F Grace, MD, MMSc 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   3
  •   2014/07/20
* This entry means the parameter is not applicable or has not been set.